We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
+5.44%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$143M
AUM Growth
-$58.9M
(-29%)
Cap. Flow
-$87.8M
Cap. Flow
% of AUM
-61.39%
Top 10 Holdings %
Top 10 Hldgs %
99.77%
Holding
14
New
2
Increased
1
Reduced
1
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MannKind Corp
MNKD
|
+$5.44M |
| 2 |
Achieve Life Sciences
ACHV
|
+$807K |
| 3 |
Opko Health
OPK
|
+$113K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASRT
Assertio
ASRT
|
+$6.24M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$4.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLXP
1
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $27M | 18.87% |
300,000
| – | – |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $15.6M | 10.92% |
938,543
-242,857
| -21% | -$4.15M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.5B
| $12.8M | 8.97% |
182,300
| – | – |
|
|
4
Achieve Life Sciences
ACHV
$626M
| $8.62M | 6.03% |
470
+46
| +11% | +$807K |
|
|
5
MannKind Corp
MNKD
$1.28B
| $5.57M | 3.89% |
+214,084
| New | +$5.44M |
|
|
ECYT
6
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $4.97M | 3.48% |
465,763
| – | – |
|
|
SPHS
7
DELISTED
Sophiris Bio, Inc.
SPHS
| $1.85M | 1.29% |
500,000
| – | – |
|
|
DNDN
8
DELISTED
DENDREON CORPORATION
DNDN
| $238K | 0.17% |
79,600
| – | – |
|
|
9
Opko Health
OPK
$921M
| $94K | 0.07% |
+11,195
| New | +$113K |
|
|
ASRT
10
DELISTED
Assertio
ASRT
| – | – |
-13,932
| Closed | -$6.24M |
|
|
AMBI
11
DELISTED
Ambit Biosciences Corp
AMBI
| $0 | ﹤0.01% |
46
| – | – |
|
Similar funds
HA
SGAM
CCA
FWTB
NIM
RMCM
FC
SC
Tang Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, Tang Capital Management held 14 positions worth $143M, down 29% from $202M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Tang Capital Management withdrew a net $87.8M in Q4 2013, closing 1 position and reducing 1 holding. Its most notable exit was Assertio, an estimated $6.24M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 27% a quarter earlier.
Against the trend, Tang Capital Management opened a new position in MannKind Corp worth $5.57M.
- Tang Capital Management's largest Q4 2013 buy was MannKind Corp: 214,084 shares worth $5.57M.
- Tang Capital Management added most to Achieve Life Sciences in Q4 2013, an estimated $807K increase.
- Tang Capital Management's biggest Q4 2013 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $4.15M.
- Tang Capital Management fully exited Assertio in Q4 2013, selling an estimated $6.24M.
- Tang Capital Management's ten largest holdings make up 100% of its $143M portfolio in Q4 2013.
- Tang Capital Management opened 2 new positions and closed 1 in Q4 2013.
- Tang Capital Management's portfolio value fell 29% quarter-over-quarter to $143M.
Based on Tang Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.